The CBD oil market is expected to grow at a CAGR of 32.5% during the forecast period from 2025 to 2033, starting from US$ 1168.3 Mn in 2021. CBD oil-based products are gaining its popularity and consumers nowadays are becoming more inclined towards using CBD oil-based products for treating a number of health problems such as insomnia, chronic pain, anxiety, among others.
The global endotracheal tube market is projected to expand at a CAGR of 6.5% during the forecast period of 2025 to 2033. Increasing incidences of chronic diseases such as cardiovascular disease, cancer, and other respiratory diseases have led to an increase in the number of surgical procedures requiring endotracheal tubes. According to the 2019 World Health Organization report, respiratory diseases are the leading cause of death worldwide, accounting for approximately 4.0 million deaths annually.
Blockchain technology in healthcare is being acknowledged to have revolutionary impact on the healthcare system enabling its complete transformation through digitization. As digitization of all industries has continued to expand over the decades, the blockchain technology entered the market in 2016, despite its introduction in 2008. Blockchain technology has touched several industries deployed with vast information, technologies and artificial intelligence. The concept of blockchain represents a network of blocks that continuously grow and change, that adapt to specific industry. Blockchain is based on distributed ledgers containing facts and information.
The veterinary wearable devices market is set to reach from US$ 1,325.3 Mn in 2017 to US$ 3,704.6 Mn by 2026 at a compound annual growth rate (CAGR) of 12.1% during the forecast period from 2018 to 2026. It is noteworthy to understand that in the last decade internet of things (IoT) has played a crucial role in gathering and relaying of vital health statistics pertaining to human health. The same technology is being developed with respect to animals which helps veterinarians to gain useful clinical information for real time decision making in critical illness.
The veterinary biologics market is set to reach from US$ 21,953.8 Mn in 2021 to US$ 36,836.5 Mn by 2033 at a compound annual growth rate (CAGR) of 6.0% during the forecast period from 2025 to 2033. Veterinary biologics are medicinal products obtained from living organism and biological processes. They are employed in veterinary health science to diagnose, prevent and treat animal disease through immune-modulation.
The global varicose veins treatment devices market is increasing proficiently, expected to grow at a CAGR of 6.5%. Worldwide, the increasing burden of varicose veins along with improved therapeutic treatment options will drive the market growth. Around 40 million people in the U.S. suffer from varicose veins. Growing awareness about new sclerotherapy procedures, laser technology, and minimally invasive procedures to overcome the limitations by traditional procedures will increase the demand for advanced devices. Key factors such as increased expansion and acceptance for enzyme replacement therapy in the emerging nations, rising geriatric population, and U.S. FDA approvals for varicose veins treatment products will drive the overall market growth on a global scale.
The genital herpes treatment drugs market will be featuring magnificent growth at a compounded annual growth rate (CAGR) of 4.9% during the forecast period from 2025 to 2033. According to the latest research citing’s published by World Health Organization (WHO), approximately two-thirds of the global population under 50 years of age is infected with herpes simplex virus type 1 (HSV-1).
The equine healthcare market is expected to grow at a CAGR of 6.1% during the forecast period of 2025 to 2033, driven by key drivers such as preventive healthcare measures, advancements in diagnostics and treatment, and the rising focus on equine sports and recreation. However, challenges related to cost and accessibility pose constraints. Market segmentation underscores the dominance of specific product categories and indications, while geographic trends highlight regional variations in market dynamics.
The global explosion-proof equipment market is expected to expand at a CAGR of 5.5% during the forecast period from 2025 to 2033. The anticipated growth in demand for explosion-proof systems can be largely credited to their widespread adoption among oil & gas, energy & mining, and industrial manufacturing verticals.
The ambulatory surgery centers market is projected to grow steadily with a CAGR of 7.5% over the forecast period from 2019 to 2029. The number of outpatients has increased significantly as a result of increased public health awareness and initiatives by the government to provide ambulatory healthcare services.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.